The University of California, Los Angeles'Jonsson Comprehensive Cancer Center (JCCC) is an NCI designated matrix center conducting a wide range of translational research in the areas of laboratory, clinical and population sciences integrating the activities of 244 members. Based on the JCCC Strategic Plan, the goals of the JCCC are the integration of clinical activities to provide patient-centered care;research infrastructure improvement through technology and shared resources;increased communication within JCCC and to our many audiences;faculty support and development at all levels;and the advancement of emerging areas of research. Over the past funding cycle 70% of patients enrolled in interventional clinical trials participated in investigator-initiated studies. The tota funding base for the JCCC is $163 million with $40 million in NCI funding. Our NCI funding includes subcontracts from other institutions, of which a significant amount is derived from our partnership with California Institute of Technology. In addition, of 3,489 total publications in th reporting period, 35% were published in high-impact journals, 15% were inter-programmatic and 21% were intra-programmatic. Continuing support is requested for the following eight Programs Areas and six Shared Resources. Programs: Cancer and Stem Cell Biology*, Cancer Molecular Imaging, Cancer Nanotechnology*, Gene Regulation, Healthy and At-Risk Populations, Patients and Survivors, Signal Transduction and Therapeutics, Tumor Immunology. (*New Program Area) Shared Resources: Biostatistics, Analytical Support &Evaluation, Genomics, Flow Cytometry, Translational Pathology, Molecular Screening Shared Resource, Small Animal Imaging Shared Resource

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016042-39
Application #
8606926
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1996-12-01
Project End
2018-11-30
Budget Start
2014-03-07
Budget End
2014-11-30
Support Year
39
Fiscal Year
2014
Total Cost
$1,925,233
Indirect Cost
$675,082
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Li, Gang; Lu, Xuyang (2015) A Bayesian approach for instrumental variable analysis with censored time-to-event outcome. Stat Med 34:664-84
Epeldegui, Marta; Blom, Bianca; Uittenbogaart, Christel H (2015) BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells. Eur J Immunol 45:728-37
Bower, Julienne E; Crosswell, Alexandra D; Stanton, Annette L et al. (2015) Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 121:1231-40
Arensman, Michael D; Telesca, Donatello; Lay, Anna R et al. (2014) The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther 13:2303-14
Li, Keyu; Tavaré, Richard; Zettlitz, Kirstin A et al. (2014) Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther 13:2607-17
Ke, Ruian; Loverdo, Claude; Qi, Hangfei et al. (2014) Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. J Antimicrob Chemother 69:724-7
Fu, Maoyong; Maresh, Erin L; Helguera, Gustavo F et al. (2014) Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther 13:902-15
Leoh, Lai Sum; Morizono, Kouki; Kershaw, Kathleen M et al. (2014) Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med 16:11-27
Tong, Maomeng; McHardy, Ian; Ruegger, Paul et al. (2014) Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J 8:2193-206
De Azambuja, Katherine; Barman, Provabati; Toyama, Joy et al. (2014) Validation of an HPV16-mediated carcinogenesis mouse model. In Vivo 28:761-7

Showing the most recent 10 out of 192 publications